Age Verification Required

Imperial Peptides

By entering this site you confirm that:

  • ✓You are 18 years of age or older
  • ✓All products are for research purposes only — not for human consumption
  • ✓You are a qualified researcher, scientist, or licensed professional
  • ✓You understand these compounds are not approved by the FDA for human use

This confirmation is stored locally and will not be requested again on this device.

We are currently accepting pre-orders to ensure we have the right products in stock to best serve our customers. If you are interested in a product we do not currently carry, please do not hesitate to reach out — we welcome all product requests.
Home/Research Library/PT-141
Back to Research Library
Sexual Health

PT-141

Melanocortin Receptor Agonist

A synthetic peptide analogue of alpha-MSH that acts on melanocortin receptors centrally.

Overview

PT-141 (Bremelanotide) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). Unlike PDE5 inhibitors, PT-141 acts centrally through melanocortin receptors to influence sexual function. Research has investigated its effects on sexual arousal pathways.

Research Information

Research on PT-141 has demonstrated its ability to activate melanocortin receptors (MC3R and MC4R) in the central nervous system. Studies have investigated its effects on sexual arousal and function in both male and female animal models. Research has explored its mechanism of action through central nervous system pathways.

Research Dosage Reference

Research protocols use subcutaneous administration. Standard vials contain 10mg lyophilized powder. All dosing information is for research reference only.

Ready to Order?

Purchase high-purity PT-141 for your research.

Related Research

MT-2

Synthetic Melanocortin Receptor Agonist

Disclaimer: All information provided is for educational and research purposes only. This is not medical advice. These compounds are not approved for human use. Always consult with qualified professionals before conducting research.